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ABSTRACT 
Tubulin-binding agents are an important class of therapeutics for cancer chemotherapy. 
However, their application can be limited by systemic toxicity, poor tissue specificity, and drug 
resistance. To address these issues, modification of tubulin-binding agents with drug delivery 
systems has shown significant promise. Our group has developed a novel technology for 
delivery of small molecules and macromolecules into mammalian cells. By mimicking small 
natural cell surface receptors, cargo linked to the membrane anchor N-alkyl-3β-
cholesterylamine can be internalized through a clathrin-mediated endocytic pathway and 
trapped in early/recycling endosomes. Co-administration with endosome-disruptive peptides 
enable 3β-cholesterylamine-conjugated cargo to escape these early/recycling endosomes of 
living mammalian cells. This approach can be highly efficient as evidenced by fluorescence-
based assays. To explore the potential of this system for delivery of tubulin-binding agents, we 
designed and synthesized a series of colchicine- and colchinol methyl ether-cholesterylamine 
conjugates. These disulfide-linked compounds were designed to deliver tubulin-binding agents 
into early/recycling endosomes to minimize their cytotoxic effect. Only upon the activation by an 
endosome disruptive peptide would these conjugates be released into the cytosol. Cleavage of 
a disulfide bond in a linker region by glutathione provides a mechanism of release. Cell viability 
assays demonstrated that carefully-designed conjugates to cholesterylamine can substantially 
reduce the toxicity of tubulin-binding agents by trapping the warhead in endosomes. After 
activation by endosome disruptive peptides, conjugates with a glutamic acid residue in the linker 
region proximal to colchinol methyl ether showed high potency against several cancer cell lines 
including Jurkat lymphocytes (T-cell leukemia) and PC3 prostate cancer cells.   
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Chapter 1. Tubulin-Binding Agents in Cancer Chemotherapy 
 
 
1.1  Introduction 
Microtubules are components of the cytoskeleton with important roles in a variety of 
cellular functions including intracellular transport, maintenance of cell shape, polarity, cell 
signaling, and mitosis.1 During mitosis, microtubules form the mitotic spindle that transports 
daughter chromosomes to separate poles of the dividing cell. Microtubules are noncovalent 
polymers of α- and β-tubulin heterodimers assembled in a filamentous tube-shaped structure. 
Consequently, tubulin-binding agents are widely used in cancer chemotherapy due to the 
important role of microtubules in cell division.2 Their efficacy has been demonstrated in the clinic 
for the treatment of a wide variety of human cancers, including breast, lung, ovarian, and 
prostate, as well as haematological malignancies and childhood cancers.3  
Tubulin-binding agents are known to interact with tubulin at four binding sites: the 
laulimalide, taxane/epothilone, vinca alkaloid, and colchicine sites (Figure 1.1). Similar to 
paclitaxel, laulimalide can promote the tubulin-microtubule assembly, but binds to a different site 
on microtubules (Figure 1.2).4 Taxanes, including docetaxel and paclitaxel, bind to polymerized 
microtubules at the inner surface of the β subunit (Figure 1.2), and are widely used in the 
treatment of lung, breast, ovarian and bladder cancers. Taxanes promote tubulin stabilization, 
thereby interfering with tubulin dynamics.5 Vinca alkaloids generally bind with high affinity to one 
or a few tubulin molecules at the tip of microtubules and promote depolymerization of 
microtubules. (Figure 1.2).6 The fourth group of microtubule interfering agents is represented by 
colchicine, which also induces microtubule depolymerization of microtubules (Figure 1.2).6  
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Figure 1.1: X-ray structure of colchicine-β tubulin binding complex (PDB code: 1SA0).  
 
In contrast to agents that bind to the other three sites, colchicine binds with high affinity 
to tubulin and is copolymerized into microtubules. Colchicine binding to β-tubulin results in a 
curved tubulin dimer. This prevents the formation of a straight structure, due to a steric clash 
between colchicine and α-tubulin, which inhibits microtubule assembly.7 
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Figure 1.2: Tubulin binding sites of microtubule targeting agents. 
 
1.2 Tubulin-Binding Agents in Cancer Chemotherapy 
 
Vinca domain-binding agents 
Vinca alkaloids were originally isolated from the Vinca rosea plant, Catharanthus roseus. 
The first two vinca alkaloids identified, vinblastine and vincristine, are almost structurally 
identical, except a formyl group is attached to the dihydroindole nitrogen in vincristine, whereas 
vinblastine has a methyl group at that position. Vinblastine and vincristine bind to the β-subunit 
of tubulin at a distinct region called the vinca-binding domain,8 thereby inhibiting the assembly of 
microtubules. They are usually used to treat breast cancer, testicular cancer, Hodgkin's 
lymphoma, and small cell lung cancer.9, 10 Vinorelbine is a semisynthetic derivative of 
vinblastine, which has an eight-membered ring in the catharanthine moiety instead of the nine-
membered ring in the parent vinblastine. This compound has been approved for the treatment of 
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breast cancer.11 Vinflunine (Figure 1.3), a novel fluorinated compound obtained by superacid 
transformation of vinorelbine in the presence of fluorhydric acid, has recently been approved for 
second-line treatment of bladder cancer.12  
The dolastatin family, originally isolated from marine peptides of the ocean shell-less 
mollusc Dolabella auricularia, includes dolastatin 10, cemadotin, tasidotin and auristatin PE 
(Figure 1.3).13 These agents all associate with the vinca-binding domain of β-tubulin. Phase II 
clinical trials of dolastatin 10 in patients have been conducted.14 Performance against solid 
tumors was lacking, but dolastatin 10 remains a good candidate for developing more active 
analogues. Auristatin PE (Figure 1.3) is a novel synthetic analogue of dolastatin 10. It maintains 
potent antitumor activity and is associated with less toxicity than its parent compound dolastatin 
10. Moreover, in addition to its efficacy in the inhibition and disruption of the microtubule 
assembly, auristatin PE has a dual action in blocking blood supply to tumor vasculature.15 
Auristatin PE combines both conventional antitumor activity and distinct antitumor vascular 
activity to make it a potentially attractive tool for cancer therapy. 
Eribulin (Figure 1.3) is a fully synthetic macrocyclic ketone analogue of the marine 
sponge natural product halichondrin B, which binds in the vinca domain of tubulin.16 Eribulin 
exerts its anticancer effects by triggering apoptosis of cancer cells following prolonged and 
irreversible mitotic blockade.17 Eribulin mesylate was approved by the U.S. Food and Drug 
Administration on November 15, 2010, to treat patients with metastatic breast cancer who 
relapsed after treatment with anthracyclines and taxanes. 
 
Taxane domain-binding agents 
Paclitaxel and its semi-synthetic analogue docetaxel were among the most important 
new additions to the chemotherapeutic arsenal in the late twentieth century. Paclitaxel (taxol, 
Bristol-Myers Squibb) is a natural product isolated from Taxus brevifolia.18 Docetaxel (taxotere, 
Sanofi-Aventis) is a water-soluble, semisynthetic analogue of the naturally occurring precursor 
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10-deacetylbaccatin III, which was isolated from Taxus baccata. Both paclitaxel and docetaxel 
occupy the same binding site in the β-subunit of tubulin called the taxane binding site.19 
Paclitaxel and docetaxel have been used for the treatment of many types of cancer, 
demonstrating significant activity against solid tumors.20, 21 Besides paclitaxel and docetaxel, 
cabazitaxel (Jevtana, Sanofi-Aventis, Figure 1.3) displayed promising results in patients with 
breast cancer or prostate cancer and has recently been approved by the US Food and Drug 
Administration for the treatment of metastatic hormone-resistant prostate cancer after the failure 
of docetaxel treatment.22 
Epothilones were originally isolated from the myxobacterium Sorangium cellulosum. 
They are a promising novel family of agents for cancer treatment as they are active against 
taxane-resistant tumors.23 As of September 2008, epothilones A to F have been identified and 
characterized. Compared with taxanes, epothilones have good water solubility and do not seem 
to be substrates for the P-gp efflux pump.24 Epothilone B (patupilone, Novartis) has been 
evaluated in clinical trials against a variety of solid tumors. Patupilone crosses the blood-brain 
barrier and has shown activity in patients with recurrent or progressive brain metastases from 
non small cell lung cancer (NSCLC).25  
Ixabepilone (Figure 1.3) is a semi-synthetic derivative of epothilone B. Compared with 
the parent compound epothilone B, ixabepilone has improved solubility, low plasma protein 
binding, and high metabolic stability.26 Like the natural epothilones A and B, ixabepilone 
stabilizes microtubules and induces apoptosis, and is currently approved for the treatment of 
advanced taxane-resistant breast cancer in the United States. KOS-862, also known as 
epothilone D, has a mechanism of action similar to that of taxanes, leading to microtubule 
stabilization and mitotic arrest. KOS-862 has shown superior in vivo anticancer activity relative 
to patupilone.27 In phase 2 trials, KOS-862 showed activity in patients with breast cancer and 
NSCLC.28 KOS-1584 (9,10-didehydroepothilone D, Figure 1.3) is a novel analogue of KOS-862. 
This compound was identified in screens for epothilone analogues with higher potency and 
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improved pharmacologic and pharmacokinetic (PK) properties. KOS-1584 has shown 
approximately 3- to 12-fold higher potency compared with KOS-862, enhanced tumor tissue 
penetration, and reduced exposure to selected tissues including the CNS.29 An ongoing phase II 
trial is evaluating the efficacy of KOS-1584 in patients with advanced or metastatic (stage IIIB-
IV) NSCLC.30 
 
Figure 1.3: Chemical structures of tubulin-binding agents organized according to their binding 
domains. 
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Colchicine domain-binding agents 
Colchicine and ZD6126 
Colchicine, which was extracted from the poisonous meadow saffron Colchicum 
autumnale L, was the first tubulin destabilizing agent. It has been used for many years as an 
unapproved drug to treat gout, familial Mediterranean fever and pericarditis.31 In 2009, U.S. 
Food and Drug Administration (FDA) approved colchicine as a monotherapy to treat familial 
Mediterranean fever and acute gout flares. Since cancer cells undergo mitosis at a significantly 
increased rate, and colchicine can effectively inhibit mitosis, cancer cells are often more 
susceptible to colchicine poisoning than normal cells. Consequently, colchicine is being 
investigated as an anticancer drug. However, the therapeutic value of colchicine against cancer 
is limited by its low therapeutic index.32 
Since the late 1990s, N-acetylcolchicinol-O-phosphate (ZD6126), a compound that 
resembles colchicine and binds in the colchicine site of tubulin, has undergone extensive 
development as a vascular-disrupting agent.33 ZD6126 is a water-soluble phosphate prodrug of 
N-acetylcolchinol structurally very similar to colchicine with potential antiangiogenesis and 
antineoplastic activities.33 ZD6126 was developed by AstraZeneca for the treatment of 
metastatic colorectal cancer. However the study was terminated at phase II due to apparent 
cardiotoxicity at pharmacological doses.34  
 
Combretastatin A4 (CA4) and its analogues 
Combretastatins are an exciting family of microtubule-targeted agents. They are lead 
compounds for vascular-targeting agents or vascular-disrupting agents, compounds that 
produce rapid disruption of tumour blood flow, probably by effects on the microtubule 
cytoskeleton of endothelial cells. Combretastatin A4 (CA4), isolated from the Combretum 
caffrum tree, is the most potent naturally occurring combretastatin known in regards to both 
tubulin binding ability and cytotoxicity.35 However, in Phase I trials, CA4 was found to induce 
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unusual toxicities such as tumor pain, ataxia and cardiovascular modifications, including 
prolonged corrected QT interval and electrocardiogram modifications consistent with acute 
coronary syndrome.36, 37 CA4P (Zybrestat, fosbretabulin) is the prodrug of CA4 developed by 
OxiGene. Currently, it is being evaluated in clinical trials as a treatment for solid tumors. Several 
phase II studies using CA4P have been completed or are ongoing for different type of cancers 
including anaplastic thyroid cancer, non-small cell lung cancer and relapsed ovarian cancer.38  
AVE8062 (ombrabulin, Figure 1.3) is another CA4 analogue which exerts its anticancer 
activity through disrupting blood vessel formation in tumors. Compared with CA4, it has 
improved water solubility and is orally available. It is effective against a number of cancer cells 
that are resistant to taxanes.39 In a phase I study, the combination of AVE8062 with docetaxel 
was well tolerated. A phase III study is currently ongoing for advanced cancer treatment.40 
Phenstatin is another CA4 analogue with the double bond of CA4 replaced by a carbonyl 
group. Phenstatin showed strong cytotoxicity and antitubulin activity similar to CA4, but it is 
more stable compared with CA4, which is unstable in vivo due to the transformation from the 
active cis-configuration to the more stable but inactive trans-configuration.41 CC-5079 is a 1,1-
diarylethene analogue of CA4, which is called isocombretastatin A. CC-5079 has dual inhibitory 
activity against tubulin polymerization and phosphodiesterase-4 (PDE4). It shows both 
antiangiogenic and antitumor activities. CC-5079 can arrest cell cycle in the G2/M phase, 
increase phosphorylation of G2/M checkpoint proteins, and induce apoptosis.42 
 
Miscellaneous agents targeting the colchicine binding site 
Podophyllotoxin (Figure 1.3), otherwise known as podofilox, is a non-alkaloid toxic lignan 
extracted from the roots and rhizomes of Podophyllum species. Podophyllotoxin competitively 
inhibits binding of colchicine to tubulin. It binds to tubulin more rapidly than colchicine does. The 
utilization of Podophyllotoxin as a lead in drug design has resulted in useful cancer fighting 
drugs such asetoposide, teniposide, and etoposidephosphate.43 
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Steganacin, a new lignan lactone from the alcoholic extract of Steganataenia araliacea 
Hochest, has significant antitumor activity in vivo against P388 leukemia cells in mice and in 
vitro against cells derived from a human carcinoma of the nasopharynx (KB).44 Steganacin 
prevents the formation of the spindle. This suggested that steganacin, like other spindle poisons 
such as colchicine and podophyllotoxin, exerts its antimitotic activity through an effect on 
spindle microtubules.44 
Curacin A, originally purified as a major lipid component from a strain of the cyano 
bacterium Lyngbya majuscule isolated in Curaçao, is a potent inhibitor of cell growth and 
mitosis. It binds rapidly and tightly at the colchicine site of tubulin.45 Poor water-solubility and 
lack of chemical stability prevent the clinical development of curacin A, but synthetic analogues 
with improved bioavailability may provide more promise. 
2-Methoxyestradiol (2-ME) is an endogenous estrogen metabolite, formed by hepatic 
cytochrome P450 2-hydroxylation of β-estradiol and 2-O-methylation via catechol O-
methyltransferase. This metabolite has attracted interest because of its potent inhibition of 
tumor vasculature and tumor cell growth.46 Studies have shown that 2-ME is metabolized by 
conjugation at positions 3 and 17 and oxidation at position 17, forming inactive metabolites. In 
order to make metabolically stable analogues with improved anti-tubulin properties, ENMD-1198 
(Figure 1.3) was generated via chemical modification at 3 and 17 position. This agent also binds 
to the colchicine binding site in tubulin. Studies showed that ENMD-1198 was very potent at 
inhibiting endothelial cell proliferation, motility, migration, and morphogenesis. Furthermore, 
ENMD-1198 is able to quickly disrupt vascular structures.47 
 
Other tubulin-binding agents 
Laulimalide (Figure 1.3) is a potent, structurally unique microtubule-stabilizing agent 
originally isolated from the marine sponge Cacospongia mycofijiensis.48 Laulimalide exhibits an 
activity profile different from other microtubule-binding agents, notably including effectiveness 
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against paclitaxel-resistant cells. Unfortunately, laulimalide has a narrow therapeutic index and 
is intrinsically unstable; therefore it is considered unsuitable for clinical trials. 
Noscapine (Figure 1.3) is an alkaloid from plants of the Papaveraceae family. Currently, 
phase I/II clinical trials with noscapine for non–Hodgkin's lymphoma and multiple myeloma are 
in progress (ClinicalTrials.gov identifier: NCT00912899). Furthermore, several analogues of 
noscapine with increased potency in humans are under investigation as cancer therapeutics.49 
Estramustine (Figure 1.3) is a chemotherapy agent used for the treatment of prostate 
carcinoma. Estramustine inhibits growth and induces mitotic arrest in many types of cultured 
cells, including the human prostate carcinoma cell lines DU 145 and PC3. It was reported that 
the antimitotic mechanism of action of estramustine may be due to binding to a novel site in 
tubulin and stabilization of microtubule dynamics.50 
 
Table 1.1: Tubulin-binding agents, their diverse binding sites and therapeutic uses. 
Binding domain Related drugs or 
analogues 
Therapeutic uses References 
Vinca domain Vinblastine Hodgkin's lymphoma, 
testicular cancer 
9 
 Vincristine Leukaemia, small cell lung 
cancer 
10 
 Vinorelbine Breast cancer 11 
 Vinflunine Bladder cancer 12 
 Dolastatins (such as 
auristatin PE) 
Potential vascular-targeting 
agent 
13-15 
 Eribulin mesylate Metastatic breast cancer 16-17 
Taxane domain Paclitaxel Lung, breast and ovarian 20 
11 
 
 
cancer 
 Docetaxel Breast and prostate cancer 21 
 Cabazitaxel Breast and prostate cancer 22 
 Epothilone B Non small cell lung cancer 25 
 Ixabepilone Taxane-resistant breast 
cancer 
26 
 Epothilone D Breast and lung cancer 27, 28 
 KOS-1584 Non small cell lung cancer 29, 30 
Colchicine domain Colchicine Non-neoplastic diseases 
(gout, familial 
Mediterranean fever) 
31 
 ZD6126 Colorectal cancer 33 
 Combretastatins (CA4, 
CA4P, Ombrabulin, 
Phenstatin, CC-5079) 
Vascular-targetting agents 
for the treatment of many 
types of cancer 
35-42 
 Steganacin Nasopharynx cancer 44 
 2-Methoxyestradiol and 
its analogue ENMD-
1198 
Ovarian cancer 46, 47 
Other binding sites Laulimalide N/A 48 
 Noscapine Non–Hodgkin's lymphoma 49 
 Estramustine Prostate cancer 50 
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1.3  Limitations of Tubulin-Binding Agents in Cancer Chemotherapy 
 
Three major shortcomings limit the application of tubulin-binding agents in cancer 
chemotherapy. These include undesired toxicity, poor tissue specificity and drug resistance. 
Among the side effects caused by tubulin-binding agents, neuropathy is a chief limitation in the 
use of these agents.51 For example, vincristine induces neurotoxicity characterized by a 
peripheral, symmetric mixed sensory-motor, and autonomic polyneuropathy.52 Hematopoietic 
toxicity is also frequently observed with microtubule-targeted agents, with subtle differences 
between compounds in the same family. For example, in phase I studies neutropenia was one 
of the dose-limiting toxicities observed with ixabepilone.53 
Another major limitation of using tubulin-targeting agents clinically is innate and acquired 
drug resistance. The most common form of clinical resistance is over-expression of the MDR1 
gene, which encodes the P-glycoprotein (Pgp) drug efflux pump.54 This membrane-associated 
ATP-binding cassette (ABC) transporter is over expressed in many tumor cell lines, including 
tissues of the liver, kidney, and gastrointestinal tract. Over-expression of Pgp decreases 
intracellular drug levels and is associated with poor response to tubulin-binding agents including 
taxanes and vinca alkaloids.55 Besides over-expression of ABC transporters, over-expression of 
the βIII-tubulin isoform is another significant mechanism of resistance. Among the eight 
identified β-tubulin isotypes in humans, over-expression of class III β-tubulin promotes 
resistance to tubulin-binding agents such as paclitaxel and vinorelbine.56 Clinical development 
of new tubulin-binding agents that circumvents both of these drug resistance mechanisms could 
have advantages for patients with drug resistant tumors. 
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1.4  Future Development of Tubulin-Binding Agents  
 
Microtubules are a highly-validated target in cancer therapy. Consequently, many efforts 
have been made to develop novel agents directed against this target. The development of novel 
tubulin-binding agents with better properties is of significant interest. 
One approach is focused on the discovery tubulin-binding agents that are not substrates 
for efflux pumps and other modifications of drugs to confer lower affinity for transporting 
proteins. Several promising agents have been reported in preclinical studies. These include 
peloruside A, taccalonolides, coumarins and cyclostreptin (Figure 1.4).57 
 
Figure 1.4: Chemical structures of peloruside A, taccalonolide A and cyclostrepin. 
 
The tumor vasculature is an attractive new target for cancer therapy. An advantage is 
the relatively easy access of therapeutic agents to the target. It is known that some compounds 
can inhibit the formation of new blood vessels (inhibit the process of angiogenesis) or shut down 
existing ones. Tumor cells die quickly after cutting off the oxygen supply. Moreover, some of 
these agents act only with tumor vasculature and do not interact with normal tissues. Many anti-
vascular agents are similar to colchicine and bind to the colchicine binding site on β-tubulin. 
Development of novel agents targeting the colchicine binding site (which is not used by any 
currently approved anticancer drugs) may be a promising approach.58 
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Another attractive strategy involves vectorization of tubulin-binding agents to tumor cells 
using delivery systems, such as liposomes, polymers, antibodies, or cell-penetrating peptides.59 
Maytansine is a potent tubulin-binding agent that induces mitotic arrest and kills tumor cells at 
subnanomolar concentrations. However, its side effects and lack of tumor specificity have 
prevented successful clinical use. Antibody-conjugated maytansine derivatives have been 
developed to overcome these drawbacks. Trastuzumab–DM1, a maytansinoid conjugated to 
trastuzumab, a therapeutic antibody targeting the human epidermal growth factor receptor 2 
(ERBB2) has show good efficacy in clinical trials against metastatic breast cancer.59 
 
1.5  Conclusion 
 
Tubulin-binding agents are an important class of compounds for cancer chemotherapy. 
Disparities in their tubulin binding properties lead to differences in their mechanisms of action 
with a significant impact on the efficacy or toxicity profile of each agent. Because of numerous 
adverse effects and limitations in use, new tubulin-binding agents with better properties are 
needed. Especially desired are improvements in antitumor activity, toxicity profile, drug 
formulation, and pharmacology. Among the approaches for development of novel tubulin-
binding agents with better properties, modifying these agents with delivery systems has 
significant promise. Delivery systems might enable considerable amounts of tubulin-binding 
agents to be administrated to the tumor without toxic effects towards normal tissues. Research 
on binary systems designed to deliver tubulin-binding agents into early endosomes of tumor 
cells and release these agents is described in this thesis. 
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Chapter 2.  A Binary Drug Delivery System: Release of Disulfide-Linked Tubulin-    
Binding Agents Mediated by Endosome Disruptive Peptides 
 
 
2.1 Introduction 
 
Drug delivery is an important field in the pharmaceutical sciences. Controlled drug 
delivery can improve bioavailability by preventing metabolism and enhancing cellular uptake. By 
controlling the rate of drug release, drug delivery systems can maintain drug concentrations 
within a therapeutic window and reduce side effects by targeting of drugs to diseased tissues 
and cells.1  
Historically, therapeutic agents have predominately comprised small molecules with 
molecular weights below a few hundred. However, recent advances have led to the discovery of 
novel therapeutics including proteins, monoclonal antibodies, and nucleic acids.2-4 Most of these 
agents are impermeable to cell membranes and delivery into cells poses new challenges 
beyond those encountered with traditional small-molecule therapeutics. To circumvent 
membrane barriers, some of these agents have been combined with delivery systems such as 
liposomes,5 polymers,6 cell-penetrating peptides (CPPs),7, 8 or include ligands targeting 
internalizing cell surface receptors.9-11 However, the underlying mechanisms of these methods 
are often not well understood, and the delivery efficiencies of these methods vary substantially.  
Receptor-mediated endocytosis (RME) is a major mechanism used by mammalian cells 
for the uptake of macromolecules from extracellular fluid.12 RME of cholesterol-laden LDL 
particles by the LDL receptor (LDLR) has been extensively characterized,13,14 and key features 
of this process are illustrated in Figure 2.1. In this process, extracellular ligands (LDL particles) 
bind the LDL receptor, a natural cell surface receptor that clusters in dynamic regions of cellular 
plasma membranes. By actively pinching off to form intracellular vesicles, these membrane 
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micro domains are internalized, encapsulating ligand-receptor complexes in the cytoplasm. 
These vesicles fuse to form early/sorting endosomes that are acidified (pH ~ 6) through the 
activation of proton pumps, conditions that promote the dissociation of many ligands from 
receptors. Free receptors often traffic back to the cell surface through related recycling 
endosomes.15 Meanwhile, dissociated ligands are generally transported to more acidic late 
endosomes and lysosomes (pH ~ 5), where hydrolases and other enzymes promote their 
degradation. 
 
 
Figure 2.1: Receptor-mediated endocytosis of the LDL in animal cell. Figure courtesy of 
Professor Blake R. Peterson. 
 
Because of the high abundance of cholesterol in cellular plasma membranes, and its 
role in cycling between the cell surface and early/recycling endosomes,16 our group has focused 
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on using analogues of cholesterol, particularly derivatives of cholesterylamine, to construct 
synthetic compounds that mimic cellular uptake and trafficking properties of natural cell surface 
receptors.17 Cholesterol derivatives have been used to facilitate the delivery of siRNA,18 
enhance DNA transfection,19 probe cellular membrane subdomains,20 and have been proposed 
for tumor targeting applications.21 The cationic cholesterol mimic 3β-amino-5-cholestene (3β-
cholesterylamine, 1, Figure 2.2) is of particular interest because of its high affinity for 
phospholipid membranes.22 Derivatives of 3β-amino-5-cholestene have been used to construct 
photoaffinity probes23 and related aminosteroids.24 N-Alkyl derivatives of 3β-amino-5-cholestene 
can insert into plasma membranes of living mammalian cells and cycle between the cell surface 
and early/recycling endosomes, mimicking the membrane trafficking of many cell surface 
receptors.25  
Cargo linked to N-alkyl-3β-cholesterylamines and many other delivery systems can 
become trapped in endosomes of living mammalian cells. Because many biologically active 
molecules have targets either in the cytoplasm or nucleus, the entrapment of these molecules in 
endosomes can limit efficacy. To address this problem, several approaches for disruption of 
endosomes have been explored. Many viruses enter host cells via endocytic mechanisms and 
use specific molecules on viral capsid, called fusion proteins (FPs), to disrupt endosomes and 
release genetic material into the cytoplasm.26 To mimic this endosome disruption strategy, viral 
fusion proteins have been incorporated into liposomes, 27 combined with polymers, 28 or linked to 
CPPs29 to facilitate the release of cargo molecules. Although these peptides can be prepared on 
solid phase, the subtantial length of many these peptides makes the synthesis costly, and some 
of these peptides are toxic to cells. In 2006, Thomas Weber and his coworkers identified a pH-
dependent lytic peptide termed PC4 (2, Figure 2.2), using phage display technology.30 PC4 was 
shown to promote pH-dependent leakage of compounds from liposomes comparable to some 
viral fusion peptides, but this peptide is significantly smaller than most viral peptides (12 amino 
acids). Inspired by studies of PC4, our group designed and synthesized an N-alkyl-3β-
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cholesterylamine-capped membrane lytic peptide (cholesterylamine-PC4, 3, Figure 2.2). To 
investigate whether this compound (3) can promote endosome disruption and release of cargo 
trapped in early/recycling endosomes, we designed and synthesized another derivative of N-
alkyl-3β-cholesterylamine comprising the green fluorophore 5-carboxyfluorescein linked through 
a disulfide bond (4, Figure 2.2).  
Figure 2.2: Structures of 3β-cholesterylamine (1), PC4 (2), cholesterylamine-PC4 (3) and 
disulfide probe (4). 
 
We hypothesized that when added to mammalian cells, derivatives of N-alkyl-3β-
cholesterylamine would become incorporated in cellular plasma membranes and engage a 
membrane trafficking pathway that involves rapid cycling between the cell surface and 
intracellular endosomes, similar to many natural cell surface receptors.25 Because 
early/recycling endosomes are thought to be oxidizing,31 we hypothesized that the disulfide 
bond of 4 should be relatively stable in these compartments. However, if compound 4 were 
exposed to reduced glutathione (GSH), a thiol present at mM concentrations in the cytosol, this 
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functional group would be cleaved.32 Correspondingly, disruption of early/recycling endosomes 
loaded with 4 by compound 3 was proposed as a mechanism to enable GSH to access these 
compartments, reduce the disulfide bond of 4, and release the soluble fluorophore 5 into the 
cytoplasm and nucleus of cells (Figure 2.3). 33 
 
 
 
 
Figure 2.3: Proposed molecular mechanism for the selective release of disulfide-linker 
fluorophore from early/recycling endosomes mediated by 3. Panel A: Products of cleavage of 4 
by glutathione. Panel B: Mechanism of release of fluorophore 5 into the cytosol and nucleus of 
mammalian cells. 
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To investigate this concept, living Jurkat lymphocytes were treated with molecular probe 
4 in the presence or absence of the cholesterylamine-PC4 lipopeptide (3). Confocal laser 
scanning microscopy revealed that, when combined with 3, the green fluorescence of 4 was 
released from entrapment in early/recycling endosomes and fluorescence was observed the 
cytosol and nucleus (Figure 2.4).33  
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Confocal laser scanning and DIC micrographs of living Jurkat lymphocytes treated 
with cholesterylamine-PC4 (3) and disulfide probe (4). Panel A: Jurkat lymphocytes were 
treated with 4 only (2.5 µM) for 12 h at 37 oC. Panel B: Jurkat lymphocytes were treated with 3 
(2 µM) and 4 (2.5 µM) for 12 h at 37 oC. Adapted from Sun, Q., Cai, S., Peterson, B. J. Am. 
Chem. Soc. 2008, 130, 10064-10065.  
 
Starting with cholesterylamine-PC4 (3) as a lead, two postdoctoral fellows, Dr. Ze Li and 
Dr. Chamani Perera in our group designed and synthesized analogues (7-9, Figure 2.5) aimed 
to facilitate the disruption of endosomes. Fluorescence-based assays run by Mr. David Hymel in 
our group demonstrated that these compounds were potent endosome disruptors (Figure 2.6). 
 
Figure 2.5: Structures of N-alkyl-3β-cholesterylamine-capped peptides (7-9) 
A. Treatment for 12 h with: 4 (2.5 µM)  
 
B. Treatment for 12 h with: 4 (2.5 µM) + 3 (2 µM) 
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Analogues of Cholesterylamine-PC4 in Jurkat lymphocytes
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Figure 2.6: Efficacy and potency of analogues of cholesterylamine-PC4 (7-9) in Jurkat 
lymphocytes. Release of fluorophore (2.5 µM) into the cytoplasm results in enhanced cellular 
fluorescence that was measured by flow cytometry. 
 
Inspired by the results from fluorescence-based assays of endosome disruption, we 
sought to explore a potential application of our novel early/recycling endosome-targeting system 
for drug delivery. We describe in this chapter the synthesis of novel disulfide-linked 
cholesterylamine conjugates of colchicine and colchinol methyl ether designed to localize the 
tubulin-binding moiety in early/recycling endosomes to minimize its cytotoxic effect. Only upon 
the activation by an endosome disruptive peptide would the tubulin-binding moiety be released 
into the cytosol and kill the cells. This binary drug delivery strategy was expected to modulate 
the cytotoxic effect of a nonselective cytotoxin by trapping the prodrug in early/recycling 
endosomes. The endosome disruptive peptide would be used to release the toxic headgroup in 
a controlled manner (Figure 2.7). 
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Figure 2.7: Proposed molecular mechanism for the selective release of a disulfide-linked 
cytotoxin from early/recycling endosomes mediated by an endosome disruptive peptide. 
 
2.2 Design, Synthesis, Evaluation of Disulfide-Linked Cholesterylamine Conjugates of 
Colchicine and Colchinol methyl ether 
 
Deacetylcolchicine trifluoroacetate (13) was synthesized as previously reported in 
literature (Figure 2.8).34 We designed and synthesized four derivatives of this agent linked to N-
alkyl-3β-cholesterylamines35, 36 (16-19, Figure 2.8). Three of these compounds (16, 18, 19) have 
a disulfide bond that is designed to allow cleavage by reduced glutathione. Compound 17, 
prepared as a control, replaces the disulfide of 16 with a more stable amide. 
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Figure 2.8: Synthesis of deacetylcolchicine trifluoroacetate and colchicine-cholesterylamine 
conjugates (16-19). Reagents and conditions: (a) Boc2O, DMAP, TEA, CH3CN, 100 
oC, 3 h; (b) 
2M NaOCH3 in CH3OH, 22 
oC, 1 h; (c) TFA, 22 oC, 5 min; (d) solid phase synthesis on 2-
chlorotrityl resin; (e) cleavage from resin with acetic acid/TFE/DCM (1: 2: 7 by volume);  (f) 
HATU, DIEA, CH2Cl2, 22 
oC, 16 h; (g) TFA/CH2Cl2 (3: 17, by volume), 22 
oC, 3 h; (h) Fmoc-β-
Ala-OH/Fmoc-Glu(t-Bu)-β-Ala-OH, HATU, DIEA, CH2Cl2, 22 
oC, 16 h; (i) Si-piperazine, DIEA, 
DMF, 22 oC, 16 h; (j) 14, HATU, DIEA, CH2Cl2, 22 
oC, 16 h. 
 
We hypothesized that the colchicine-cholesterylamine conjugates (16-19) would cycle 
between the cell surface and intracellular endosomes when added to mammalian cells. 
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Because the partitioning of structurally similar compounds between the plasma membrane and 
endosomes is affected by the structure of the linker region proximal to the membrane anchor,33 
in 16-19, two glutamic acid residues were installed in this region to enhance the localization of 
these compounds in endosomes compared to the plasma membrane. In order to explore the 
effect of the linker region proximal to the tubulin-binding moiety, β-alanine and β-alanine-
glutamic acid were included in the linker region of 18 and 19. Based on our previous studies of 
fluorescent probes, the disulfide bond of compounds (16, 18, 19) should be relatively stable in 
endosomes. However, we hypothesized that the endosome disruptive peptide would disrupt 
early/recycling endosomes loaded with 16, 18, or 19, enable GSH to access these 
compartments, reduce the disulfide bond, and release the toxic tubulin-binding moiety to kill 
cells. 
To investigate this concept, Jurkat lymphocytes were treated with 16-19 in the presence 
or absence of endosome disruptive peptides (Figure 2.5). As hypothesized, cell viability assays 
showed that the colchicine-cholesterylamine conjugate 16 (IC50 ~ 400 nM) reduced the toxicity 
of the parent compound colchicine (IC50 ~ 2.1 nM), consistent with the proposed mechanism of 
trapping the warhead in endosomes (Figure 2.9). However, the IC50 of 16 alone indicated that 
this compound still possesses some toxicity, which is likely due to slight reduction of the 
disulfide in endosomes during the 48 hour incubation. This interpretation is supported by the 
fact that control compound 17 where the disulfide is replaced with an amide was less toxic, with 
essentially no toxicity observed at 500 nM. These results established that the cytotoxicity of a 
tubulin-binding agent can be controlled by linking these molecules to the endosome-targeting N-
alkyl-3β-cholesterylamine membrane anchor. On the other hand, the combination of 16 and 7 
(IC50 ~ 50 nM), was nearly 8 fold as potent as 16 alone, indicating that activation by 7 induced 
the release of the colchicine-derived cytotoxin headgroup (Figure 2.9). 
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Figure 2.9. Toxicity to Jurkat lymphocytes of 16 and controls (10, 17) in the presence or 
absence of endosome disruptor 7 (2 μM). The viability of the cells was determined by flow 
cytometry after incubation with compounds (0 to 1 μM) for 48 h at 37 oC. 
 
Compared with the parent compound colchicine, cell viability assays showed that the 
colchicine-cholesterylamine conjugate 18 (IC50 ~ 21 nM) had a 10-fold reduction in toxicity and 
19 (IC50 ~ 56 nM) had a 25-fold reduction in toxicity (Figure 2.10). On the other hand, the 
combination of 18 and 7 (IC50 ~ 2.6 nM), was almost 8 fold as potent as 18 alone; the 
combination of 19 and 7 (IC50 ~ 2.3 nM), was nearly 25 fold as potent as 19 alone, indicating 
that 7 could facilitate the disruption of early endosomes and release the toxic cargo. In 
combination with 7, both 18 and 19 were more potent than 16, indicating the linker region 
proximal to colchicine might affect the activity of cytotoxin headgroup after the cleavage of 
disulfide bond. However, the estimated IC50 of 18 and 19 showed that these two compounds 
alone retained high levels of toxicity. We hypothesized that this high toxicity in the absence of 7 
may relate to the high electrophilicity of seven-membered tropone ring in colchicine, which could 
promote off-target effects due to reaction with biomolecules. Therefore, we sought to examine 
another related cytotoxin with potentially better properties in this type of delivery system. 
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Figure 2.10: Toxicity to Jurkat lymphocytes of compounds (18, 19) and controls (10, 17) in the 
presence or absence of 7 (2 μM). The viability of the cells was determined by flow cytometry 
after incubation with compounds (0 to 1 μM) for 48 h at 37 oC. 
 
 
N-Acetylcolchinol methyl ether (NACM, 23) is a potent analogue of colchicine with a 
methoxy-substituted benzenoid ring instead of the methoxy-substituted tropone ring (Figure 
2.11).37 Alteration of the tropone ring is known to yield agents that are more potent than 
colchicine both against tumor cells and as inhibitors of tubulin.38 Deacetylcolchinol methyl ether 
hydrochloride (24) was prepared according to procedures reported in literature (Figure 2.11).39,40 
To explore our binary drug delivery system with this cytotoxin,  we designed and synthesized 
four colchinol methyl ether derivates linked to N-alkyl-3β-cholesterylamine. Compounds (25, 27, 
28) have a reducible disulfide bond in the linker region, whereas compound 26, prepared as a 
negative control, has an amide bond at that position. Similar to the colchicine-cholesterylamine 
conjugates 18 and 19, β-alanine and β-alanine-glutamic acid were separately installed to 27 and 
28 to study the effects of the linker region proximal to the colchinol methyl ether (Figure 2.11). 
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Figure 2.11: Synthesis of deacetylcolchinol methyl ether hydrochloride and colchinol methyl 
ether-cholesterylamine conjugates (25-30). Reagents and conditions: (a) 0.1 N HCl, HOAc, 100 
oC, 2 h; (b) NaOH, I2, NaI, H2O, 22 
oC, 3 h; (c) Zn, HOAc, 100 oC; (d) MeI, K2CO3, acetone, 56 
oC; (e) 2N HCl, MeOH, 90 oC; (f) 14/15, EDC, HOBt, CH2Cl2, 22 
oC, 16 h; (g) TFA/CH2Cl2 (3: 17, 
by volume), 22 oC, 3 h; (h) Fmoc-β-Ala-OH/Fmoc-Glu(t-Bu)-β-Ala-OH/Fmoc-Gly-β-Ala-
OH//Fmoc-Glu(t-Bu)-Gly-β-Ala-OH, EDC, HOBt, CH2Cl2, 22 
oC, 16 h; (i) Si-piperazine, DIEA, 
DMF, 22 oC, 16 h; (j) 14, HATU, DIEA, CH2Cl2, 22 
oC, 16 h. 
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Flow cytometry-based cell viability assays showed the IC50 values of colchinol methyl 
ether-cholesterylamine conjugates (25, 27, 28) were greater than 1 μM (Figure 2.12, Panel A), 
suggesting that the toxicity of the parent compound colchinol methyl ether was significantly 
reduced by trapping the warhead in endosomes. On the other hand, the combination of 28 and 
endosome disruptor 7 (IC50 ~ 110 nM, Figure 2.12, Panel B), was over 9 times more potent than 
28 alone. However, in combination with 7, both 25 and 27 did not differ substantially in their 
potency, indicating that the linker region proximal to the colchinol methyl ether strongly affects 
the activity of cytotoxin headgroup. In an additional set of experiments, we investigated how a 
more potent endosome disruptive peptide (8) would affect the cytotoxicity of compounds (25-
28). Similar to the previous results, only the combination of 28 and 8 (IC50 ~ 150 nM) showed 
high potency (Figure 2.12, Panel C), indicating that the β-alanine-glutamic acid sequence is 
beneficial for improving the potency of colchinol methyl ether-cholesterylamine conjugate. 
To further investigate the effect of the linker region proximal to colchinol methyl ether on 
the potency of colchinol methyl ether-cholesterylamine conjugate, two other compounds (29, 30) 
were designed and synthesized (Figure 2.11). Compared with 28, the glutamic acid in the linker 
region was replaced by glycine in 29, and 30 has one additional glycine between the β-alanine 
and glutamic acid.  
Both 29 and 30 were essentially non-toxic to Jurkat lymphocytes at a concentration of 1 
μM (Figure 2.13). In combination with 8, the potency of compound 30 (IC50 ~ 27 nM) was 
increased by over 35 fold, but compound 29 did not show enhanced potency (Figure 2.13). 
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Figure 2.12: Toxicity to Jurkat lymphocytes of compounds (25, 27, 28) and controls (23, 26) in 
the absence or presence of endosome disruptor 7 or 8. Panel A: Toxicity to Jurkat lymphocytes. 
Panel B: Toxicity to Jurkat lymphocytes in the presence of 7 (2 μM). Panel C: Toxicity to Jurkat 
lymphocytes in the presence of 8 (100 nM). The viability of the cells was determined by flow 
cytometry based assay after incubation with compounds (0 to 1 μM) for 48 h at 37 oC. 
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This result, together with the previous study of 28, demonstrated that the glutamic acid in 
the linker region was important for maintaining the potency of colchinol methyl ether-
cholesterylamine conjugates in the presence of the endosome disruptive peptide. 
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Figure 2.13: Toxicity to Jurkat lymphocytes of compounds (29, 30) and controls (23) in the 
presence or absence of endosome disruptor 8 (100 nM). The viability of the cells was 
determined by flow cytometry after incubation with compounds (0 to 1 μM) for 48 h at 37 oC. 
 
As described previously, the N-alkyl-3β-cholesterylamine derived drug delivery system 
was able to reduce the toxicity of the parent compound colchinol methyl ether, and in 
combination with endosome disruptive peptides, some colchinol methyl ether-cholesterylamine 
conjugates showed good potency against the proliferation of Jurkat lymphocytes. Based on 
these results, we decided to study whether our binary delivery system might be effective in other 
cancer cell lines, PC3, DU145 and A549. PC3 and DU145 are human prostate cancer cell 
lines. These cells are useful in investigating the biochemical changes in advanced prostatic 
cancer cells and in assessing their response to chemotherapeutic agents.41 DU145 cells have 
moderate metastatic potential compared to PC3 cells which have high metastatic potential.42 
A549 cells are adenocarcinomic human alveolar basal epithelial cells. These cells can be used 
for evaluation of chemotherapy agents against lung cancer.43 
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We designed and synthesized two additional colchinol methyl ether-cholesterylamine 
conjugates (31, 33) for exploring a potential application of our binary delivery system in different 
cancer cell lines. Compound 31 has a β-alanine-β-alanine-glutamic acid sequence in the linker 
region proximal to colchinol methyl ether and 33 was prepared as a negative control with an 
amide bond replacing the disulfide bond (Figure 2.14). 
 
Figure 2.14. Synthesis of colchinol methyl ether-cholesterylamine conjugates (31, 33). Reagents 
and conditions: (a) Fmoc-Glu(t-Bu)-β-Ala-β-Ala-OH, EDC, HOBt, CH2Cl2, 22 
oC, 16 h; (b) Si-
piperazine, DIEA, DMF, 22 oC, 16 h; (c) 14, HATU, DIEA, CH2Cl2, 22 
oC, 16 h; (d) TFA/CH2Cl2 
(3: 17, by volume), 22 oC, 3 h; (e) solid phase synthesis on 2-chlorotrityl resin; (f) cleavage from 
resin with acetic acid/TFE/DCM (1: 2: 7 by volume); (g) HATU, DIEA, CH2Cl2, 22 
oC, 16 h.   
 
Flow cytometry-based cell viability assays were employed to study the toxicities of 31 
and 33 in Jurkat lymphocytes, PC3 cells, DU145 cells and A549 cells. The endosome disruptive 
peptide 9 (Figure 2.5) was used to facilitate the release of the cytotoxin. In Jurkat lymphocytes, 
the combination of 31 and 9 (IC50 ~ 36 nM) was over 25 fold more potent than 31 alone (Figure 
2.15, Panel A). Also in combination with 9, the potency of 31 (IC50 ~ 112 nM) to inhibit the  
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Figure 2.15: Toxicity to four cancer cell lines of 31 and controls (23, 33) in the presence or 
absence of endosome disruptor 9 (1 μM). Panel A: Toxicity to Jurkat lymphocytes. Panel B: 
Toxicity to PC3 cells. Panel C: Toxicity to DU145 cells. Panel D: Toxicity to A549 cells. The 
viability of the cells was determined by flow cytometry after incubation with compounds (0 to 1 
μM) for 48 h at 37 oC. 
 
 
proliferation of PC3 cells was increased by over 9 fold (Figure 2.15, Panel B). However, 
compared with 31 alone the potency of 31 in DU145 and A549 cells was not enhanced in 
combination with 9 (Figure 2.15, Panel C and Panel D). These results showed that our binary 
delivery system was effective for delivering cytotoxins into some types of cancer cells, however, 
some other cancer cell lines appear to be less sensitive to this delivery system. 
 
2.3 Conclusions 
 
In summary, a major challenge associated with cancer chemotherapy is the low 
therapeutic index of many cytotoxic agents, including tubulin binding agents. As a strategy to 
modulate the cytotoxic effect of a tubulin binding agent, we designed and synthesized disulfide-
linked colchicine and colchinol methyl ether derivatives linked to the membrane anchor N-alkyl-
3β-cholesterylamine to selectively localize these compounds in early/recycling endosomes. Cell 
viability assays indicated that the cytotoxic effect of colchinol methyl ether could be diminished 
D. Toxicity of NACM (23) and Related 
Conjugates to A549 cells 
 
 
0
25
50
75
100
-9 -8 -7 -6 -5
23, IC50 = 20 nM
31, IC50 > 1 M
33, IC50 > 1 M
23 + 9 (1 M), IC50 = 21 nM
31 + 9 (1 M), IC50 > 1 M
33 + 9 (1 M), IC50 > 1 M
0
9, IC50 > 1 M
Conc (log M)
V
ia
b
il
it
y 
a
t 
7
2
 h
 (
%
)
40 
 
 
by trapping the molecule in sealed endocytic vesicles and reactivated by disrupting the 
endosomes with the endosome disruptive peptide to release a thiol derivative. The linker region 
proximal to the colchinol methyl ether was found to strongly affect the activity of the cytotoxin. 
Comparison of the toxicities of colchinol methyl ether-cholesterylamine conjugates (25-30, 31, 
33) in the presence of an endosome disruptive peptide demonstrated that insertion of a glutamic 
acid residue in the linker region was able to significantly increase the potency. This negatively 
charged glutamic acid residue may improve activity by minimizing efflux of the colchinol methyl 
ether warhead crossing the plasma membrane, consequently enhancing its accumulation in the 
cytosol. This binary cytotoxin delivery system was demonstrated to be effective in inhibiting the 
proliferation of Jurkat lymphocytes and PC3 cells, but other cancer cell lines such as DU145 
and A549 cells were much less sensitive. We hypothesize that DU145 cells and A549 cells may 
express drug efflux pumps that decrease levels of the intracellular cytotoxin or the endosome 
disruptive peptides may show lower efficacy in these cell lines for unknown reasons. 
 
2.4 Future directions 
 
The success of chemotherapy can be limited by insufficient drug concentrations in 
tumors, systemic toxicity, a lack of selectivity for tumor cells over normal cells, and the 
appearance of drug-resistant tumor cells.44-46 One promising area for improving tumor selectivity 
is tumor-enzyme activated chemotherapy.47 Tumor-enzyme activated chemotherapy is usually a 
two-step approach. In the first step, a drug-activating enzyme over expressed by tumors is 
identified. In the second step, a nontoxic prodrug, a substrate of this enzyme, is administered 
systemically.44, 45 The net gain is that a systemically administered prodrug can be converted into 
a high local concentration of an active anticancer drug in tumors. Tumor-enzyme activated 
chemotherapy shows particular promise for targeting membrane-type matrix metalloproteinases 
(MT-MMPs) for activation of anticancer agents. MT-MMPs function to break down the 
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extracellular matrix to facilitate tumor invasion and also play a major role in controlling tumor cell 
growth, migration, differentiation, and ultimately metastasis.48 ICT2588, a non-toxic peptide-
conjugated colchiceinamide, was shown to be selectively metabolized by MT-MMPs, particularly 
membrane-type 1 matrix metalloproteinases (MT1-MMP), to release the active agent in the 
tumor (Figure 2.16)49, 50.Importantly, significant growth delay of human fibrosarcoma HT1080 
xenografts without associated systemic toxicity was observed.49 
Figure 2.16: Structure of ICT2588, a compound shown to be selectively cleaved by MT-MMPs 
to release colchiceinamide 
 
Inspired by the results from this research, we sought to design and synthesize peptides 
that can be selectively metabolized by MT-MMPs expressed in tumor to release an active 
endosome disruptive peptide. The activation of the endosome disruptive peptide selectively in 
the tumor, coupled with colchinol methyl ether-cholesterylamine conjugates, might lead to 
significant antitumor effect with a greater therapeutic index. These studies are currently 
underway. 
Aptamers are oligonucleotides or peptides capable of specific and tight binding to their 
target. Several unique properties of aptamers make them attractive tools for use in targeted 
drug delivery. The advantages of aptamers over other drug delivery system include high binding 
affinity, greater stability, ease of synthesis, and lower production cost.51 The possible targets of 
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aptamers can exhibit great diversity ranging from small molecules to proteins and whole 
cells.52,53 One important class of targets for aptamers is cell surface receptors. Most cell surface 
proteins cycle intracellularly to some extent, and many surface receptors are actively 
internalized in response to ligand binding.54 Therefore, aptamers that bind cell surface receptors 
have been exploited for the delivery of a variety of cargoes into cells.55 In future research, we 
are planning to investigate whether aptamers might be useful for targeting cell surface receptors 
and delivery of endosome disruptive peptides and cytotoxins. One cell surface receptor of 
interest is the prostate-specific membrane antigen (PSMA), a type 2 integral membrane 
glycoprotein expressed on the surface of prostate carcinoma and the neovasculature of most 
other solid tumors. The antigen is abundantly expressed at all stages of the cancer and is 
therefore an attractive target for cancer immunotherapy and imaging.56.57  
In addition to aptamers and antibodies, small molecules can be used to target some cell 
surface receptors. For example, Professor Philip Low and coworkers conducted in silico docking 
studies and identified 2-[3-(1, 3-dicarboxypropyl)-ureido]pentanedioic acid (DUPA) as a ligand of 
PSMA with high affinity.58  
Inspired by the results from this research, the construction of a DUPA based delivery 
system (Figure 2.17), designed to selectively transport probes or cytotoxins into the prostate 
cancer cells through the binding of DUPA with PSMA, is currently underway. Combined with 
endosome disruptive peptides, this approach may enhance therapeutic index of anticancer 
agents. 
 
Figure 2.17: Structure of DUPA and proposed DUPA based delivery system. 
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2.5 Experimental Section 
 
2.5.1 General 
         
Chemical reagents were obtained from Sigma Aldrich, TCI, or Alfa Aesar. Solvents were 
from Sigma Aldrich or Fisher Sci. Commercial grade reagents were used without further 
purification unless otherwise noted. Detailed synthetic procedures and characterization data of 
deacetylcolchicine trifluoroacetate (13) and deacetylcolchinol methyl ether hydrochloride (24) 
have been previously described.34, 39, 40 Compound 7 was prepared by Dr. Ze Li, a former 
postdoctoral fellow in the Peterson laboratory. Compounds 8 and 9 were prepared by Dr. 
Chamani Perera of the Peterson laboratory. Anhydrous solvents were obtained after passage 
through a drying column of a solvent purification system from GlassContour (Laguna Beach, 
CA). All reactions were performed under an atmosphere of dry nitrogen. Reactions were 
monitored by analytical thin-layer chromatography on plates coated with 0.25 mm silica gel 60 
F254 (EMD Chemicals). TLC plates were visualized by UV irradiation (254 nm) or stained with a 
solution of phosphomolybdic acid in ethanol (20%). Flash column chromatography employed 
ICN SiliTech Silica Gel (32-63 μm). Purification by preparative reverse phase HPLC employed 
an Agilent 1200 preparative pump/gradient extension instrument equipped with a Hamilton 
PRP-1 (polystyrene-divinylbenzene) reverse phase column (7 μm particle size, 21.5 mm × 25 
cm). The HPLC flow rate was maintained at 25 mL/min for the entire run unless otherwise 
noted. NMR spectra were obtained with Bruker DRX-400 instruments with chemical shifts 
reported in parts per million (ppm, δ) referenced to either CDCl3 (
1H 7.27 ppm; 13C 77.2 ppm), 
MeOH-d4 (
1H 4.80 ppm; 13C 49.2 ppm), DMSO-d6 (
1H 2.50 ppm; 13C 39.5 ppm), or (CH3)4Si (0 
ppm). Low-resolution mass spectra were obtained from Waters Micromass ZQ Mass 
Spectrometer. Peaks are reported as m/z. 
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2.5.2 Synthetic Procedures and Compound Characterization Data 
 
LRMS (ESI+) m/z 2339.2 (M+H-, C126H79N21O22 requires 2339.4). 
Figure 2.18: Analytical HPLC profile of compound 7 after purification by preparative HPLC. 
Retention time = 17.2 min. Purity by HPLC > 95%. 
 
 
LRMS (ESI+) m/z 2717.7 (M+H-, C142H209N23O30 requires 2717.6). 
 
Figure 2.19: Analytical HPLC profile of compound 8 after purification by preparative HPLC. 
Retention time = 16.7 min. Purity by HPLC > 99%. 
 
 
Compound 7 
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UV detection at 254 nm 
UV detection at 254 nm 
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LRMS (ESI+) m/z 2842.9 (M+H-, C146H212N26O32 requires 2842.6). 
 
 
Figure 2.20: Analytical HPLC profile of compound 9 after purification by preparative HPLC. 
Retention time = 17.0 min. Purity by HPLC > 95%. 
 
 
 
(16S,19S)-16,19-bis(3-(tert-butoxy)-3-oxopropyl)-5-((3S,8S,9S,10R,13R,14S,17R)-10,13-
dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-
1H-cyclopenta[a]phenanthren-3-yl)-2,2-dimethyl-4,10,14,17,20-pentaoxo-3-oxa-24,25-
dithia-5,11,15,18,21-pentaazaoctacosan-28-oic acid (14). Peptide synthesis employed a 
Bohdan-2080 MiniBlock and standard N-Fmoc methodology. The peptide was constructed with 
2-Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using 5-{(tert-butoxycarbonyl) [(3β)-cholest-
5-en-3yl]amino}pentanoic acid,25 Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid and 
the following Fmoc-protected amino acids: Fmoc-β-Ala-OH, Fmoc-Glu(t-Bu)-OH. Amino acids 
were consecutively coupled to the resin by addition of DMF solution (2 mL) of amino acid (4.0 
eq.), HATU (3.8 eq.) and DIEA (8.0 eq.) with shaking at 22 oC for 2 h. Deprotection of Fmoc 
carbamates on the resin was carried out by addition of piperidine (20%) in DMF (2 mL for 5 min 
Compound 9 UV detection at 254 nm 
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followed by 2 mL for 3 min followed by 2mL for 2 min (×2)). After completing all the steps of 
coupling reactions, the peptide was cleaved from the resin by treatment with TFA/TFE/CH2Cl2 
(1:2:7) with shaking for 2 h. The resin was removed by filtration and washed with CH2Cl2 (2 mL 
×3). The filtrates were combined and concentrated in vacuo. The crude product was dissolved 
in MeOH (1 mL) and purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% 
MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 10 min; retention time = 21.0 min 
(214 nm)) to afford 14 as a white solid (30 mg, 25%). LRMS (ESI+) m/z 1190.0 (M+H-, 
C63H107N5O12S2 requires 1190.7). 
 
Figure 2.21: Analytical HPLC profile of compound 14 after purification by preparative HPLC. 
Retention time = 21.0 min. Purity by HPLC > 99%. 
 
 
(16S,19S)-16,19-bis(3-(tert-butoxy)-3-oxopropyl)-5-((3S,8S,9S,10R,13R,14S,17R)-10,13-
dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-
1H-cyclopenta[a]phenanthren-3-yl)-2,2-dimethyl-4,10,14,17,20,24-hexaoxo-3-oxa-
5,11,15,18,21,25-hexaazaoctacosan-28-oic acid (15). Peptide 15 was constructed on 2-
Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using the method described for preparation of 
peptide 14. After completing all the steps of coupling reactions, the product was cleaved from 
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the resin with TFA/TFE/CH2Cl2 (1:2:7) by shaking for 2 h and purified by preparative reverse-
phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% 
TFA over 10 min; retention time = 20.0 min (214 nm)) to afford 15 as a white solid (52 mg, 
45%). LRMS (ESI-) m/z 1169.3 (M+H-, C64H108N6O13 requires 1169.6). 
 
 
Figure 2.22: Analytical HPLC profile of compound 15 after purification by preparative HPLC. 
Retention time = 20.0 min. Purity by HPLC > 99%. 
 
 
(S)-5-(((S)-4-carboxy-1-oxo-1-((2-((3-oxo-3-(((S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-
tetrahydrobenzo[a]heptalen-7-yl)amino)propyl)disulfanyl)ethyl)amino)butan-2-yl)amino)-
4-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl) 
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)amino)pentanamido)propanamido)-5-oxopentanoic acid (16). 13 (9 mg, 0.025 mmol) was 
dissolved in anhydrous CH2Cl2 (1 mL). To a solution of 14 (36 mg, 0.03 mmol) were added 
HATU (14 mg, 0.037 mmol) and DIEA (13 mg, 0.1 mmol). After 30 min, the CH2Cl2 solution of 
deacetylcolchicine was added. The reaction was stirred for 16 h at 22 oC and then was 
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concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing TFA (15%) and 
stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude product was 
purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % 
TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 18.3 min (254 nm)), which 
afforded 16 (17 mg, 52%) as an off white solid. LRMS (ESI-) m/z 1317.6 (M+H-, C70H103N6O14S2 
requires 1317.7). 
 
Figure 2.23: Analytical HPLC profile of compound 16 after purification by preparative HPLC. 
Retention time = 18.3 min. Purity by HPLC > 99%. 
 
(S)-5-(((S)-4-carboxy-1-oxo-1-((3-oxo-3-((3-oxo-3-(((S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-
tetrahydrobenzo[a]heptalen-7-yl)amino)propyl)amino)propyl)amino)butan-2-yl)amino)-4-
(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)amino)pentanamido)propanamido)-5-oxopentanoic acid (17). 13 (9 mg, 0.025 mmol) was 
dissolved in anhydrous CH2Cl2 (1 mL). To a solution of 15 (35 mg, 0.03 mmol) were added 
HATU (14 mg, 0.037 mmol) and DIEA (13 mg, 0.1 mmol). After 30 min, the CH2Cl2 solution of 
deacetylcolchicine was added. The reaction was stirred for 16 h at 22 oC and then was 
concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing TFA (15%) and 
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stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude product was 
purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % 
TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 17.2 min (254 nm)), which 
afforded 17 (22 mg, 70%) as an off white solid. LRMS (ESI-) m/z 1296.8 (M+H-, C71H105N7O15 
requires 1296.8). 
 
 
Figure 2.24: Analytical HPLC profile of compound 17 after purification by preparative HPLC. 
Retention time = 17.2 min. Purity by HPLC > 99%. 
 
 
(14S,17S)-14-(2-carboxyethyl)-17-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-
((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-1,5,13,16-tetraoxo-1-
(((S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)amino)-8,9-
dithia-4,12,15-triazaicosan-20-oic acid (18). 13 (12 mg, 0.034 mmol) was dissolved in 
anhydrous CH2Cl2 (2 mL). To a solution of Fmoc-β-Ala-OH (13 mg, 0.041 mmol) were added 
HATU (19 mg, 0.051 mmol) and DIEA (13 mg, 0.14 mmol). After 30 min, the CH2Cl2 solution of 
deacetylcolchicine was added. The reaction was stirred for 16 h at 22 oC. This solution was 
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diluted with CH2Cl2 (10 mL) and washed with aqueous NaOH (0.1 M, 5 mL) and saturated 
aqueous NaCl (5 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was dissolved in DMF (2 mL) and to this solution were added silica-bound 
piperazine (1.07 mmol/g, 0.17 mmol, 158 mg) and DIEA (22 mg, 0.17 mmol). The reaction was 
stirred for 16 h at 22 oC. Silica-bound piperazine was removed by filtration and washed with 
CH2Cl2 (3×2 mL). The filtrates were concentrated in vacuo and the derived primary amine 
(deacetylcolchicine-β-Ala-NH2) was dissolved in CH2Cl2 (1 mL). To a solution of 14 (40 mg, 
0.034 mmol) were added HATU (19 mg, 0.051 mmol) and DIEA (13 mg, 0.14 mmol). After 30 
min, the CH2Cl2 solution of the primary amine was added. The reaction was stirred for 16 h at 22 
oC and then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing 
TFA (15%) and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude 
product was purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, 
and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 17.8 min (254 
nm)), which afforded 18 (7 mg, 15%) as a white solid. LRMS (ESI-) m/z 1388.5 (M-H-, 
C73H108N7O15S2 requires 1388.8). 
 
Figure 2.25: Analytical HPLC profile of compound 18 after purification by preparative HPLC. 
Retention time = 17.8 min. Purity by HPLC > 95%. 
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(4S,15S,18S)-15-(2-carboxyethyl)-18-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-6,14,17-trioxo-4-((3-
oxo-3-(((S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-
yl)amino)propyl)carbamoyl)-9,10-dithia-5,13,16-triazahenicosane-1,21-dioic acid (19). A 
side-chain protected dipeptide sequence (Fmoc-Glu(t-Bu)-β-Ala-OH) was synthesized on 2-
Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using the method described for preparation of 
peptide 14. Using this dipeptide (20 mg, 0.04 mmol) instead of Fmoc-β-Ala-OH, the primary 
amine (deacetylcolchicine-β-Ala-Glu(t-Bu)-NH2) was synthesized with the same method for 
preparation of deacetylcolchicine-β-Ala-NH2. The primary amine was dissolved in CH2Cl2 (1 
mL). To a solution of 14 (40 mg, 0.034 mmol) were added HATU (19 mg, 0.051 mmol) and 
DIEA (18 mg, 0.14 mmol). After 30 min, the CH2Cl2 solution of the primary amine was added. 
The reaction was stirred for 16 h at 22 oC and then was concentrated in vacuo. The residue was 
dissolved in CH2Cl2 (5 mL) containing TFA (15%) and stirred for 3 h at 22 
oC. The reaction was 
concentrated in vacuo, and the crude product was purified by preparative reverse-phase HPLC 
(gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 
min; retention time = 17.1 min (254 nm)), which afforded 19 (9 mg, 17%) as a white solid. LRMS 
(ESI-) m/z 1515.4 (M-H-, C78H116N8O18S2 requires 1515.8). 
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Figure 2.26: Analytical HPLC profile of compound 19 after purification by preparative HPLC. 
Retention time = 17.1 min. Purity by HPLC > 99%. 
 
 
(4S)-5-(((2S)-4-carboxy-1-oxo-1-((2-((3-oxo-3-(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-
dibenzo[a,c][7]annulen-5-yl)amino)propyl)disulfanyl)ethyl)amino)butan-2-yl)amino)-4-(3-
(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)amino)pentanamido)propanamido)-5-oxopentanoic acid (25). 24 (11 mg, 0.03 mmol) was 
dissolved in anhydrous CH2Cl2 (1 mL). To a solution of 14 (43 mg, 0.036 mmol) were added 
EDC (8.6 mg, 0.045 mmol) and HOBt (6.9 mg, 0.045 mmol). After 30 min, the CH2Cl2 solution of 
deacetylcolchinol methyl ether was added. The reaction was stirred for 16 h at 22 oC and then 
was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing TFA (15%) 
and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude product was 
purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % 
TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 19.9 min (254 nm)), which 
afforded 25 (21 mg, 55%) as a white solid. LRMS (ESI-) m/z 1289.6 (M+H-, C69H104N6O13S2 
requires 1289.7). 
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Figure 2.27: Analytical HPLC profile of compound 25 after purification by preparative HPLC. 
Retention time = 19.9 min. Purity by HPLC > 95%. 
 
 
(4S)-5-(((2S)-4-carboxy-1-oxo-1-((3-oxo-3-((3-oxo-3-(((5S)-3,9,10,11-tetramethoxy-6,7-
dihydro-5H-dibenzo[a,c][7]annulen-5-yl)amino)propyl)amino)propyl)amino)butan-2-
yl)amino)-4-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-
yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-
yl)amino)pentanamido)propanamido)-5-oxopentanoic acid (26). 24 (11 mg, 0.03 mmol)  
was dissolved in anhydrous CH2Cl2 (1 mL). To a solution of 15 (42 mg, 0.036 mmol) were added 
EDC (8.6 mg, 0.045 mmol) and HOBt (6.9 mg, 0.045 mmol). After 30 min, the CH2Cl2 solution of 
deacetylcolchinol methyl ether was added. The reaction was stirred for 16 h at 22 oC and then 
was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing TFA (15%) 
and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude product was 
purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % 
TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 18.6 min (254 nm)), which 
afforded 26 (25 mg, 67%) as a white solid. LRMS (ESI-) m/z 1268.8 (M+H-, C71H105N7O15 
requires 1268.8). 
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Figure 2.28: Analytical HPLC profile of compound 26 after purification by preparative HPLC. 
Retention time = 18.6 min. Purity by HPLC > 95%. 
 
(14S,17S)-14-(2-carboxyethyl)-17-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-
((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-1,5,13,16-tetraoxo-1-
(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)amino)-8,9-
dithia-4,12,15-triazaicosan-20-oic acid (27). 24 (14 mg, 0.038 mmol) was dissolved in 
anhydrous CH2Cl2 (2 mL). To a solution of Fmoc-β-Ala-OH (14 mg, 0.045 mmol) were added 
EDC (10.9 mg, 0.057 mmol) and HOBt (8.7 mg, 0.057 mmol). After 30 min, the CH2Cl2 solution 
of deacetylcolchinol methyl ether was added. The reaction was stirred for 16 h at 22 oC. This 
solution was diluted with CH2Cl2 (10 mL) and washed with aqueous NaOH (0.1 M, 5 mL) and 
saturated aqueous NaCl (5 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was dissolved in DMF (2 mL) and to this solution were 
added silica-bound piperazine (1.07 mmol/g, 0.19 mmol, 178 mg) and DIEA (24 mg, 0.19 
mmol). The reaction was stirred for 16 h at 22 oC. Silica-bound piperazine was removed by 
filtration and washed with CH2Cl2 (3×2 mL). The filtrates were concentrated in vacuo and the 
derived primary amine (Deacetylcolchicine-β-Ala-NH2) was dissolved in CH2Cl2 (1 mL). To a 
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solution of 14 (45 mg, 0.038 mmol) were added HATU (22 mg, 0.057 mmol) and DIEA (24 mg, 
0.19 mmol). After 30 min, the CH2Cl2 solution of the primary amine was added. The reaction 
was stirred for 16 h at 22 oC and then was concentrated in vacuo. The residue was dissolved in 
CH2Cl2 (5 mL) containing TFA (15%) and stirred for 3 h at 22 
oC. The reaction was concentrated 
in vacuo, and the crude product was purified by preparative reverse-phase HPLC (gradient: 
89.95% H2O, 9.95% MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; 
retention time = 18.5 min (254 nm)), which afforded 27 (10 mg, 20%) as a white solid. LRMS 
(ESI-) m/z 1360.6 (M+H-, C73H108N7O15S2 requires 1360.7). 
 
Figure 2.29: Analytical HPLC profile of compound 27 after purification by preparative HPLC. 
Retention time = 18.5 min. Purity by HPLC > 99%. 
 
 
(4S,15S,18S)-15-(2-carboxyethyl)-18-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-6,14,17-trioxo-4-((3-
oxo-3-(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-
yl)amino)propyl)carbamoyl)-9,10-dithia-5,13,16-triazahenicosane-1,21-dioic acid (28). A 
primary amine (deacetylcolchinol methyl ether-β-Ala-Glu(t-Bu)-NH2) was synthesized with the 
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same method for preparation of deacetylcolchicine-β-Ala-Glu(t-Bu)-NH2using deacetylcolchinol 
methyl ether hydrochloride instead of deacetylcolchicine. The primary amine (15 mg, 0.025 
mmol) was dissolved in CH2Cl2 (1 mL). To a solution of 14 (36 mg, 0.03 mmol) were added 
HATU (14 mg, 0.038 mmol) and DIEA (13 mg, 0.1 mmol). After 30 min, the CH2Cl2 solution of 
the primary amine was added. The reaction was stirred for 16 h at 22 oC and then was 
concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing TFA (15%) and 
stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude product was 
purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % 
TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 18.1 min (254 nm)), which 
afforded 28 (7 mg, 19%) as a white solid. LRMS (ESI-) m/z 1489.9 (M+H-, C77H116N8O17S2 
requires 1489.8).  
 
Figure 2.30: Analytical HPLC profile of compound 28 after purification by preparative HPLC. 
Retention time = 18.1 min. Purity by HPLC > 99%. 
 
 
(17S,20S)-17-(2-carboxyethyl)-20-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-
((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-1,5,8,16,19-pentaoxo-
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1-(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)amino)-11,12-
dithia-4,7,15,18-tetraazatricosan-23-oic acid (29). A dipeptide sequence (Fmoc-Gly-β-Ala-
OH) was conducted on 2-Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using the method 
described for preparation of peptide 14. Using this dipeptide (14 mg, 0.04 mmol) instead of 
Fmoc-β-Ala-OH, the primary amine (deacetylcolchinol methyl ether-β-Ala-Gly-NH2) was 
synthesized with the same method for preparation of deacetylcolchinol methyl ether-β-Ala-NH2. 
The primary amine (11 mg, 0.025 mmol) was dissolved in CH2Cl2 (1 mL). To a solution of 14 (36 
mg, 0.03 mmol) were added HATU (14 mg, 0.038 mmol) and DIEA (13 mg, 0.1 mmol). After 30 
min, the CH2Cl2 solution of the primary amine was added. The reaction was stirred for 16 h at 22 
oC and then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing 
TFA (15%) and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude 
product was purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, 
and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 18.2 min (254 
nm)), which afforded 29 (8 mg, 23%) as a white solid. LRMS (ESI-) m/z 1417.7 (M+H-, 
C74H112N8O15S2 requires 1417.8). 
 
Figure 2.31: Analytical HPLC profile of compound 29 after purification by preparative HPLC. 
Retention time = 18.2 min. Purity by HPLC > 99%. 
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(4S,15S,18S)-15-(2-carboxyethyl)-18-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-6,14,17-trioxo-4-((2-
oxo-2-((3-oxo-3-(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-
yl)amino)propyl)amino)ethyl)carbamoyl)-9,10-dithia-5,13,16-triazahenicosane-1,21-dioic 
acid (30). A side-chain protected tripeptide sequence (Fmoc-Glu(t-Bu)-Gly-β-Ala-OH) was 
conducted on 2-Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using the method described 
for preparation of peptide 14. Using this tripeptide (22 mg, 0.04 mmol) instead of Fmoc-β-Ala-
OH, the primary amine (deacetylcolchinol methyl ether-β-Ala-Gly-Glu(t-Bu)-NH2) was 
synthesized with the same method for preparation of deacetylcolchinol methyl ether-β-Ala-NH2. 
The primary amine (16 mg, 0.025 mmol) was dissolved in CH2Cl2 (1 mL). To a solution of 14 (36 
mg, 0.03 mmol) were added HATU (14 mg, 0.038 mmol) and DIEA (13 mg, 0.1 mmol). After 30 
min, the CH2Cl2 solution of the primary amine was added. The reaction was stirred for 16 h at 22 
oC and then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing 
TFA (15%) and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude 
product was purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, 
and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 17.9 min (254 
nm)), which afforded 30 (10 mg, 26%) as a white solid. LRMS (ESI-) m/z 1546.9 (M+H-, 
C79H119N9O18S2 requires 1546.8). 
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Figure 2.32: Analytical HPLC profile of compound 30 after purification by preparative HPLC. 
Retention time = 17.9 min. Purity by HPLC > 99%. 
 
 
(4S,15S,18S)-15-(2-carboxyethyl)-18-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-6,14,17-trioxo-4-((3-
oxo-3-((3-oxo-3-(((5R)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-
yl)amino)propyl)amino)propyl)carbamoyl)-9,10-dithia-5,13,16-triazahenicosane-1,21-dioic 
acid (31). A side-chain protected tripeptide sequence (Fmoc-Glu(t-Bu)-β-Ala-β-Ala-OH) was 
conducted on 2-Chlorotrityl resin (1.04 mmol/g, 96 mg, 0.1 mmol) using the method described 
for preparation of peptide 14. Using this tripeptide (22 mg, 0.04 mmol) instead of Fmoc-β-Ala-
OH, the primary amine (deacetylcolchinol methyl ether-β-Ala-β-Ala-Glu(t-Bu)-NH2) was 
synthesized with the same method for preparation of deacetylcolchinol methyl ether-β-Ala-NH2. 
The primary amine (16 mg, 0.025 mmol) was dissolved in CH2Cl2 (1 mL). To a solution of 14 (36 
mg, 0.03 mmol) were added HATU (14 mg, 0.038 mmol) and DIEA (13 mg, 0.1 mmol). After 30 
min, the CH2Cl2 solution of the primary amine was added. The reaction was stirred for 16 h at 22 
oC and then was concentrated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) containing 
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TFA (15%) and stirred for 3 h at 22 oC. The reaction was concentrated in vacuo, and the crude 
product was purified by preparative reverse-phase HPLC (gradient: 89.95% H2O, 9.95% MeCN, 
and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; retention time = 17.9 min (254 
nm)), which afforded 31 (8 mg, 21%) as a white solid. LRMS (ESI-) m/z 1560.8 (M-H-, 
C80H121N9O18S2 requires 1560.8). 
 
Figure 2.33: Analytical HPLC profile of compound 31 after purification by preparative HPLC. 
Retention time = 17.9 min. Purity by HPLC > 99%. 
 
 
(16S,19S,30S)-16,19,30-tris(3-(tert-butoxy)-3-oxopropyl)-5-((3S,8S,9S,10R,13R,14S,17R)-
10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)-2,2-dimethyl-
4,10,14,17,20,24,28,31,35-nonaoxo-3-oxa-5,11,15,18,21,25,29,32,36-
nonaazanonatriacontan-39-oic acid (32). Peptide 32 was constructed on 2-Chlorotrityl resin 
(1.04 mmol/g, 96 mg, 0.1 mmol) using the method described for preparation of peptide 14. After 
completing all the steps of coupling reactions, the product was cleaved from the resin with 
TFA/TFE/CH2Cl2 (1:2:7) by shaking for 2h and purified by preparative reverse-phase HPLC 
(gradient: 89.95% H2O, 9.95% MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 10 
UV detection at 254 nm 
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min; retention time = 20.0 min (214 nm)) to afford 32 as a white solid (55 mg, 37%). LRMS (ESI-
) m/z 1497.2 (M+H-, C79H133N9O18 requires 1496.0). 
 
Figure 2.34: Analytical HPLC profile of compound 32 after purification by preparative HPLC. 
Retention time = 20.0 min. Purity by HPLC > 99%. 
 
 
(4S,15S,18S)-15-(2-carboxyethyl)-18-(3-(5-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-
17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl)amino)pentanamido)propanamido)-6,10,14,17-tetraoxo-4-
((3-oxo-3-((3-oxo-3-(((5R)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-
5-yl)amino)propyl)amino)propyl)carbamoyl)-5,9,13,16-tetraazahenicosane-1,21-dioic acid 
(33). 24 (11 mg, 0.03 mmol) was dissolved in anhydrous CH2Cl2 (1 mL). To a solution of 32 (54 
mg, 0.036 mmol) were added EDC (8.6 mg, 0.045 mmol) and HOBt (6.9 mg, 0.045 mmol). After 
30 min, the CH2Cl2 solution of deacetylcolchinol methyl ether was added. The reaction was 
stirred for 16 h at 22 oC and then was concentrated in vacuo. The residue was dissolved in 
CH2Cl2 (5 mL) containing TFA (15%) and stirred for 3 h at 22 
oC. The reaction was concentrated 
in vacuo, and the crude product was purified by preparative reverse-phase HPLC (gradient: 
89.95% H2O, 9.95% MeCN, and 0.1 % TFA to 99.9% MeCN and 0.1% TFA over 20 min; 
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retention time = 17.0 min (254 nm)), which afforded 33 (10 mg, 22%) as a white solid. LRMS 
(ESI-) m/z 1539.9 (M+H-, C81H122N10O19 requires 1539.9). 
 
Figure 2.35: Analytical HPLC profile of compound 33 after purification by preparative HPLC. 
Retention time = 17.0 min. Purity by HPLC > 95%. 
 
2.5.3 Biological Assays and Protocols 
 
Cell culture: Jurkat lymphocytes (human acute leukemia, ATCC #TIB-152) were cultivated in 
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with Fetal Bovine Serum 
(FBS, 10%), penicillin (100 units/mL), and streptomycin (100 μg/mL). PC-3 cells (Human 
prostate cancer cells, ATCC# CRL-1435) were cultivated in Dulbecco's Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F-12) medium supplemented with Fetal Bovine Serum 
(FBS, 10%), penicillin (100 units/mL), and streptomycin (100 μg/mL). DU-145 cells (Human 
prostate cancer cells, ATCC# HTB-81) were cultivated in RPMI 1640 medium supplemented 
with Fetal Bovine Serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 μg/mL). 
A549 cells (Human lung adenocarcinoma epithelial cells, ATCC# CCL-185) were cultivated in F-
12K 1640 medium supplemented with Fetal Bovine Serum (FBS, 10%), penicillin (100 
units/mL), and streptomycin (100 μg/mL). All cell lines were propagated in a humidified 5% CO2 
incubator at 37 °C. Media used for cell culture and wash steps contained antibiotics and FBS 
unless otherwise noted. 
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Cell viability assay by flow cytometry 
Jurkat lymphocytes (2.5 × 104) in media (250 μL) were loaded on a 96-well plate. To these cells, 
increasing concentrations of compounds (10, 23, 16-19, 25-31, 33) and compounds (10, 23, 16-
19, 25-31, 33) with endosome disruptive peptide (7 at 2 μM, 8 at 100 nM, or 9 at 1 μM) in 
DMSO (final [DMSO] = 0.8%) were added. After 48 h of incubation (72 h of incubation for 31, 33 
and 31, 33 with 9 at 1 μM), propidium iodide was added to stain dead cells. Living cells were 
counted by flow cytometry. 
PC3 cells (2.5 × 104) in media (250 μL) were loaded on a 96-well plate. After incubation for 24 h, 
the media was replaced with fresh media (250 μL) containing increasing concentrations of 
compounds (23, 31, 33) and compounds (23, 31, 33) with endosome disruptive peptide (1 μM 9) 
in DMSO (final [DMSO] = 0.8%) were added. After 72 h of incubation, the cells in each well 
were washed with PBS (2 × 250 μL) and detached by treatment with a solution of trypsin (50 μL, 
5 min). After detachment, fresh media (200 μL) was added to each well and propidium iodide 
was used to stain dead cells. Living cells were counted by flow cytometry. 
DU145 cells (2.5 × 104) in media (250 μL) were loaded on a 96-well plate. After incubation for 
24 h, the media was replaced with fresh media (250 μL) containing increasing concentrations of 
compounds (23, 31, 33) and compounds (23, 31, 33) with endosome disruptive peptide (1 μM 9) 
in DMSO (final [DMSO] = 0.8%) were added. After 72 h of incubation, the cells in each well 
were washed with PBS (2 × 250 μL) and detached by treatment with a solution of trypsin (50 μL, 
5 min). After detachment, fresh media (200 μL) was added to each well and propidium iodide 
was used to stain dead cells. Living cells were counted by flow cytometry. 
A549 cells (2.5 × 104) in media (250 μL) were load on a 96-well plate. After incubation for 24 h, 
the media was replaced with fresh media (250 μL) containing increasing concentrations of 
compounds (23, 31, 33) and compounds (23, 31, 33) with endosome disruptive peptide (1 μM 9) 
in DMSO (final [DMSO] = 0.8%) were added. After 72 h of incubation, the cells in each well 
were washed with PBS (2 × 250 μL) and detached by treatment with a solution of trypsin (50 μL, 
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5 min). After detachment, fresh media (200 μL) was added to each well and propidium iodide 
was used to stain dead cells. Living cells were counted by flow cytometry. 
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